An Open-Label, Non-Comparative Trial To Evaluate The Safety, Efficacy And Pharmacokinetics Of FASLODEX (Fulvestrant) In Girls With Progressive Precocious Puberty Associated With Mccune Albright Syndrome
Latest Information Update: 11 Mar 2024
At a glance
- Drugs Fulvestrant (Primary)
- Indications Precocious puberty
- Focus Adverse reactions; Pharmacokinetics; Therapeutic Use
- Acronyms FMAS
- Sponsors AstraZeneca
- 04 Mar 2024 Status changed from active, no longer recruiting to completed.
- 18 Jan 2024 This study has been completed in Italy, according to European Clinical Trials Database record.
- 18 Jan 2024 This study has been completed in Italy, according to European Clinical Trials Database record.